Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 12, 2022

SELL
$2.2 - $4.75 $93,385 - $201,628
-42,448 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$4.12 - $20.03 $174,885 - $850,233
42,448 New
42,448 $189,000

Others Institutions Holding INKT

About MiNK Therapeutics, Inc.


  • Ticker INKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,775,100
  • Market Cap $24.7M
  • Description
  • MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...
More about INKT
Track This Portfolio

Track Gyon Technologies Capital Management, LP Portfolio

Follow Gyon Technologies Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gyon Technologies Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Gyon Technologies Capital Management, LP with notifications on news.